...
首页> 外文期刊>Journal of Medicinal Chemistry >3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases
【24h】

3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases

机译:3-氨基-苯并[d]异恶唑类作为受体酪氨酸激酶的新型多靶点抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

A series of benzoisoxazoles and benzoisothiazoles have been synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). Structure-activity relationship studies led to the identification of 3-amino benzo[d]isoxazoles, incorporating a N,N'-diphenyl urea moiety of the 4-position that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor families of RTKs. Within this series, orally bioavailable compounds possessing promising pharmacokinetic profiles were identified, and a number of compounds demonstrated in vivo efficacy in models of VEGF-stimulated vascular permeability and tumor growth. In particular, compound 50 exhibited an ED50 of 2.0 mg/kg in the VEGF-stimulated uterine edema model and 81% inhibition in the human fibrosarcoma (HT1080) tumor growth model when given orally at a dose of 10 mg/kg/day.
机译:已经合成了一系列苯并异恶唑和苯并异噻唑,并将其评估为受体酪氨酸激酶(RTK)的抑制剂。结构-活性关系研究导致鉴定出3-氨基苯并[d]异恶唑,其中并入了4-位的N,N'-二苯基脲部分,该位点可有效抑制血管内皮生长因子受体(VEGFR)和血小板-衍生的RTKs生长因子受体家族。在这个系列中,鉴定出具有前景的药代动力学特征的口服生物利用性化合物,并且许多化合物在VEGF刺激的血管通透性和肿瘤生长模型中显示出体内功效。特别地,当以10mg / kg /天的剂量口服给予时,化合物50在VEGF刺激的子宫水肿模型中显示出2.0mg / kg的ED 50,并且在人纤维肉瘤(HT1080)肿瘤生长模型中显示出81%的抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号